sheep and goats. FMDV belongs to the Aphthovirus genus of the Picornaviridae family and is 68 classified into 7 serotypes (Bachrach, 1968; Rodrigo and Dopazo, 1995; Sobrino et al., 2001) . 69
One strategy employed to control disease propagation consists of regular vaccination with an 70 inactivated whole virus antigen combined with an adjuvant (Barteling and Vreeswijk, 1991 ; 71 Grubman, 2005; Saiz et al., 2002) and has resulted in eradication of the disease in some parts 72 of the world (particularly Western Europe) (Sobrino et al., 2001 ). Pigs were protected against 73 experimental FMDV challenges 4 days after vaccination (Salt et al., 1998) The pigs were carefully observed for any adverse reaction after injection. Body 184 temperature was measured daily and 4 hours after each injection. Relative daily weight gains 185 were determined (Stellmann et al., 1989) for each pig. Some pigs were sacrificed during or at 186 the end of the assays for ethical reasons. The injected areas were examined to see whether or 187 not the injection of plasmids or expression of the encoded proteins produced lesions. Other 188 organs were also examined. 189
For the antibodies determinations, sera were collected before the first plasmid 190 injection, 1 and 2 weeks after each plasmid injection and 1, 2 and 3 weeks after the peptides 191 boost. To isolate PBMCs, total blood samples were collected before the first plasmid 192 injection, 2 weeks after each plasmid injection and 1, 2 and 3 weeks after the peptides boost. 
Statistical analysis 255
The data were analysed using the nonparametric Mann-Whitney test (Mann and Whitney, 256 1947) included in the Systat 9 software (Systat Software, Inc., Point Richmond, CA, USA). 257
This test was applied because the generated data were few in number, did not present a 258 normal distribution and consisted of unpaired quantitative data. 259
The limit of significance was 0.05 for all comparisons. 260 261 262
Results

263
Constructs 264
Two plasmid constructs encoding PrV-gB/FMDV BT were obtained. Porcine PK15 cells 265 transfected with each construct were stained with a pig PrV hyper-immune serum and an 266 antibody directed against the B cell epitope of the FMDV used here (GB1) (Fig. 1) . Each 267
PrV-gB based construct was detected by the PrV hyperimmune serum. Cells transfected with 268 the FMDV BT encoding plasmid were not detected by the GB1 anti-FMDV monoclonal 269 antibody, whereas under the same experimental conditions both PrV gB / FMDV BT chimeric 270 constructs were detected. 271 272 273
Induction of immune responses against FMDV in pigs 274
The plasmids were injected by i.m. and i.d. routes 3 times at 2-week intervals. Two weeks 275 after the last injection, individual FMDV B and T cell peptides were injected by the same 276 routes. The different injections were well tolerated. The animals grew normally and gained 277 approximately 1 kg per day in all groups in both assays. No fever peaks were observed 4 278 hours after any of the injections or during any of the daily measurements, except in 1 pig in 279 the BT-PrVgB-N term group of the 1 st assay which had a body temperature of 40.3°C, 72 280 hours after the 3 rd injection of the plasmids. This body temperature had returned to normal by 281 the next day. Several pigs in the second assay had to be euthanized for reasons unrelated to 282 immunization. One pig in the BT-PrVgB-N term group broke a hoof and had to be sacrificed 283 after the 3 rd injection. One pig in the FMDV-BT group walked with a limp and was sacrificed 284 after the second injection and another, presenting a rectal prolapse, was euthanized one week 285 after the peptides injection. Finally, one aggressive pig in the group injected with empty-286 pcDNA3 was euthanized after the peptides injection. 287 Experiments 1 and 2 were combined to determine the induction of immune responses, and the 288 average and standard deviation values were determined for each group. Insignificant amounts 289 of FMDV neutralizing antibodies were first detected 2 weeks after the second injection of 290 plasmids in the BT-PrVgB-C term group (Fig. 2) . Statistically significant titers were only 291 observed in this group 1 and 3 weeks after the FMDV B and T peptides boost (p<0.05). NAb 292 were also detected in the BT-PrV gB-C term and FMDV BT groups but the titers, in all cases, 293
were not statistically significant. Furthermore, NAb production in the FMDV BT group was 294 transient and could no longer be detected 3 weeks after the peptides boost, whereas it was still 295 observed in the BT-PrVgB-C term injected group. FMDV-specific antibodies were found at 296 the limit of detection in sera from 3 pigs in the BT-PrVgB-N term and in 2 out of 12 pigs in 297 the BT-PrVgB-C term injected groups. These antibodies were not detected in any of the other 298 groups. 299 IFN-has several immunoregulatory roles and effector functions involved in Th1-responses 300 and IL-4 plays a key role in Th2-responses (Finkelman et al., 1988; Wood and Seow, 1996) . 301
The PBMCs isolated from all these pigs were restimulated in vitro by incubation with FMDV 302 B and T cells peptides. Significant levels of IFN-mRNA were detected after the peptides 303 boost in the BT-PrVgB-N term injected group (p<0.05) (Fig. 3) . IFN-mRNA was not 304 detected in the other groups during the first assay. Significant levels were also found in the 305 BT-PrVgB-N term group one week after the peptides boost (p<0.05), but production was still 306 significantly lower than in the BT-PrVgB-C term group (p<0.05). All the other groups 307 remained negative. Significant amounts of IL-4 mRNA were only detected in the BT-PrVgB-308 N term group one week after the FMDV B and T peptides boost (p<0.05), but not in any of 309 the other groups or in the second assay (Fig. 3) . 310 311
Induction of immune responses against PrV in pigs 312
PrV neutralizing antibodies were produced in significant amounts 1 week after the third 313 injection of pcDNA3 PrV-gB (Fig. 4 ) and remained at a significant level until the end of the 314 assay. Significant amounts of PrV NAb were produced in the BT-PrVgB-N term and C term 315 groups, 2 and 3 weeks after the third plasmids injection. Nevertheless, except for the BT-PrV 316 gB-N term group 3 weeks after the third injection, the NAb titers were significantly lower 317 than in the PrV gB injected group. No significant NAb production was observed in the two 318 groups that received FMDV BT / PrV gB chimeric constructs, from the fourth week after the 319 last plasmids injection. Significant amounts of PrV-specific IgG1 were first detected 1 week 320 after the second plasmids injection in the groups of pigs injected with PrV gB or BT-PrVgB-321 N term constructs (p<0.05). IgG1 production was then maintained at a significant level until 322 the end of the assay. In contrast, production in the BT-PrV gB-C term group was 323 systematically and significantly lower from the first week after the second injection until the 324 end of the assay (p<0.01). 325 IFN-and IL-4 mRNAs production was observed in PrV-stimulated PBMCs from pigs 326 injected with PrV gB, BT-PrV gB-N term and BT-PrV gB-C term constructs from week 2 327 after the second injection to week 2 after the third injection of plasmids (p<0.05) (Fig. 5) . 328
From week 1 to week 3 after the FMDV B and T peptides injection, all 3 groups produced 329 significant amounts of IFN-mRNA except for the Bt-PrvV gB-C term group at weeks 2 and 330 3, the BT-PrV gB-N term group at week 2 and the PrV gB group at week 3. The same was 331 true for IL-4 mRNA production, except for the BT-PrV gB-C term group at weeks 1 and 2 332 after the peptides boost, and for the BT-PrV gB-N term group at week 2. No production of 333 IFN-and IL-4 RNAs was observed in the other 2 groups throughout the assay. 334 The three-dimensional structure of PrV gB has not been determined, but the X-ray structure 372 of gB ectodomain from Herpes simplex virus 1 (HSV-1) is available (Heldwein et al., 2006) . 373
PrV and HSV-1 gB share 50% identity, and the high sequence conservation strongly suggests 374 that the PrV gB adopts a structure similar to the one reported for HSV-1. FMDV-BT was 375 inserted in PrV-gB between the two B-cell epitopes located close to the N-terminus of gB 376 (BT-PrV gB-N term), and in the B-cell epitope located in the region preceding C-terminus 377 (BT-PrV gB-C term). The residues in HSV-1 gB, which correspond to the FMDV-BT 378 insertion sites in PrV gB, were identified from the alignment of the PrV and HSV-1 gB 379 sequences. The locations of the PrV insertion sites were then mapped on the HSV-1 gB 380 structure as shown in Figure 6 . For the BT-PrV gB-N term construct, the corresponding HSV-381 1 gB insertion site, residue Y179, is part of the fusion loop of HSV-1 gB. Fusion loops are 382 sequences rich in hydrophobic residues and are typically buried within the protein or in a 383 membrane, suggesting that the N-terminal FMDV-BT epitope may not be fully exposed in 384
PrV-gB. The limited accessibility of the epitope in BT-PrV gB-N term could be one of causes 385 of the inefficient recognition by immune system and low antibody titers. For the BT-PrV gB-386 C term construct, the homologous insertion site in HSV-1 gB is residue H657, which is 387 located in an exposed beta-strand of domain IV. Based on the HSV-1 gB structure, the C-388
terminal FMDV-BT epitope would likely localize to the surface of the protein, consistent with 389 its availability for recognition by immune system. 390
The results presented here show that FMDV-BT epitopes could not be detected in vitro by the 391 GB1 monoclonal antibody unless they were carried by PrV-gB. In fact, positively stained 392 cells could be visualised after transfection by either one of the PrV-gB constructs carrying 393 the FMDV-BT epitope. Moreover, PrV-gB was strongly expressed and detected when a pig 394
PrV-hyperimmune serum was used. This implies that multiple epitopes were recognized, 395 whether they were near to the insertion sites or not, suggesting that some of them were not 396 perturbed by the insertion. These findings demonstrate that the concept of PrV-gB as a carrier These results should therefore be interpreted with caution. Barnard et al. showed that the 433 production of cytokine mRNAs by FMDV-stimulated PBMCs from FMDV vaccinated pigs 434 was correlated, in most cases, with the production of cytokines (Barnard et al., 2005) . In some 435 rare cases, the cytokines were not detected, whereas the mRNAs were. We can therefore be 436 relatively confident of the results interpretation. Furthermore, the results presented here are 437 not predictive of the ability of the constructs to protect pigs against FMDV infection. This can 438 only be evaluated experimentally. Previous studies showed that although these FMDV B and 439 T cell epitopes induced no or only low titers of NAb, they were able to protect mice ( right. Y167 and H657 are the HSV-1 residues that correspond to the insertion sites of the 546 FMDV epitopes in PrV gB. HSV-1 gB fusion loops, which are the residues proposed to insert 547 into the target membrane during fusion, are marked. B, C) Only domains I and IV, 548 respectively, are shown for clarity, and insertion sites Y167 and H657 are labelled. Residue 549 Y167, which would correspond to the N-term FMDV epitope insertion, seems less accessible 550 than the fully exposed H657, which is analogous to the position where the C-term FMDV 551 epitope was added. This suggests that the latter position might be a better insertion target. 552 553 554 555 556 557 558
